Poster presented at ASH 2022 evaluating new therapeutic approaches for patients with B-cell malignancies who received prior BTKi treatment and became intolerant.
Poster presented at ASH 2022 describing the genomic analysis of patients with R/R B‑cell malignancies who were previously intolerant to certain BTKi’s.
Poster presented at ASH 2022 evaluating the use of BTKi in Japanese patients with B-cell malignancies.
Poster presented at ASH 2022 describing the potential for BCL-2 inhibition in adult patients with mature B-cell malignancies.
Oral presented at ASH 2022 describing the potential for treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with either a BCL2 inhibitor alone or a BCL2 inhibitor in combination with a BTK inhibitor.